What happens to our brains as we age? Is some form of mild cognitive impairment (MCI) inevitable? New research using AI to study brain health is being developed to see why some people develop dementia and some do not; our inherent diversity and lifestyles have tended to hinder predictions until now. Hear from Prof Zoe Kourtzi from the University of Cambridge and Dr Nick Taptiklis from Cambridge Cognition at our next early evening networking event to hear inspiring talks about research and treatments into brain health.
Speakers:
- Prof Zoe Kourtzi: University of Cambridge Department of Psychology : Early prediction of neurodegenerative disorders is key for clinical management and patient outcomes. Alzheimer’s disease (AD) is the commonest type of dementia, and is characterised by progression from normal cognition, to mild cognitive impairment (MCI), to dementia. However, not all individuals with MCI develop dementia. Predicting whether individuals with (MCI) or older people without symptoms will decline or remain stable is impeded by patient heterogeneity due to factors such as comorbidities, lifestyle and disease severity. Despite the importance of early diagnosis of AD for prognosis and personalised interventions, we still lack robust tools for predicting individual progression to dementia. We propose a novel AI-guided predictive prognostic modelling (PPM) approach that mines multimodal data to derive an individualised prognostic marker of cognitive decline at early stages of dementia or before symptoms occur. We validate our approach against routinely collected real-world patient data from memory clinics, enhancing clinical utility and translation to clinical settings. Our approach has strong potential to facilitate effective stratification of individuals based on prognostic disease trajectories, reducing patient misdiagnosis with important implications for clinical practice and discovery of personalised interventions.
- Dr Nick Taptiklis, Head of R&D Technology at Cambridge-based Cambridge Cognition : Cambridge Cognition who will give an overview of their current work in brain health. Cambridge Cognition is a leading provider of digital health solutions for brain health assessments, benefitting therapeutic areas such as Alzheimer's, MS, ADHD, Depression and more.
Cambridge Network members, current staff + students of the University of Cambridge and Anglia Ruskin University may attend fee free of charge
Non-members may attend this session at a fee of £50+VAT
